NCT02387983View on ClinicalTrials.gov

Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)

PHASE1CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

May 6, 2015

Primary Completion Date

May 2, 2016

Study Completion Date

May 2, 2016

Conditions
Fungal Infection
Interventions
DRUG

Posaconazole

Posaconazole 300 mg solid oral tablet

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02387983 - Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117) | Biotech Hunter | Biotech Hunter